Key Takeaways:
Women’s health remains among the most underresearched and underserved areas of medicine. Just 5% of global healthcare research and development funding is allocated to women’s health, with only 1% of that extending beyond cancer-related conditions, per data from 2020. Women often receive limited knowledge and guidance during reproductive transitions, especially pregnancy and menopause, whether it's feeling unsure about daily health changes or experiencing a lack of continuity and control.
Oura aims to support these concerns with two new advancements: Pregnancy Insights, a comprehensive experience that tracks how biometrics evolve throughout pregnancy, and Perimenopause Check-In, the company’s first-ever menopause tool.
“We’re expanding the Oura experience to better reflect the deeply personal and varied realities of women’s health,” said Holly Shelton, Chief Product Officer at Oura, in a press release. “From pregnancy to perimenopause, women undergo profound physiological changes that have too often been dismissed or misunderstood. For generations, many have faced these transitions without the knowledge, resources, or care they deserve, and we’re committed to changing that.”
Drawing on biometric data from more than 10,000 pregnancies, the pregnancy tool includes gestational age tracking, personalized calibration for new members. a trimester-based trend view, a “Keeping Track” tagging system with weekly messages about common symptoms, and an expanded symptom tag library. Educational content—developed with Dr. Eleni Jaswa, MD, Oura Medical Advisor and Reproductive Endocrinologist—is integrated to explain shifts in sleep, recovery, and overall well-being.
Like pregnancy, experiencing perimenopause comes with uncertainty and limited tools for support. Over one billion women worldwide deal with perimenopause or post-menopause, and Oura’s singular platform that combines symptom scoring and specialty care, through wearable data, is “the first solution of its kind,” according to the brand.
“With this offering, we’re connecting women with the care they deserve by uniting consumer health and clinical support in one seamless experience,” said Dorothy Kilroy, Chief Commercial Officer at Oura, in a press release.
The Perimenopause Check-In begins with a 12-question Menopause Rating Scale (MRS) survey. After symptoms and biometric trends are summarized, members can share the information with Oura’s women’s health partners—Midi Health, Evernow, Maven Clinic, and Progyny—that are trained to interpret biometric data and provide individualized care.
“These partnerships, and the infrastructure behind them, position Oura to lead not just in wearable tech but in delivering real outcomes across women’s health—empowering earlier interventions, more informed decisions, and better care experiences,” continued Kilroy.
Members also gain access to a content hub with science-backed guidance and real stories from women experiencing the same health changes.
This is not Oura’s first initiative addressing women’s health. In 2022, the company introduced Period Prediction, followed by Cycle Insights (2023) and Fertile Window (2024), and recently marked three years partnering with Natural Cycles, the first FDA-cleared birth control app.
“These launches represent a new chapter in health technology—one grounded in empathy and privacy, backed by science, and built on the belief that every stage of life deserves to be seen, understood, and supported,” said Shelton.
